GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc (NYSE:GSK) on January 7 and set a price target of $55.60. The same day, GSK plc ...
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA. The British drugmaker had been ...
LONDON, Jan 7 (Reuters) - GSK (GSK.L), opens new tab will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory applications, it said on ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The sale price is 60% less than ...
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the ...
Samsung Biologics, a biotechnology company based in South Korea, announced plans to open its first U.S. manufacturing facility in Rockville, according to Gov. Wes Moore‘s office. Last month, Samsung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results